Vaxcyte/$PCVX

13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX

About Vaxcyte

Vaxcyte Inc is a clinical-stage vaccine innovation company engineering high-fidelity vaccines to protect humankind from the consequences of bacterial diseases. It is developing broad-spectrum conjugate and novel protein vaccines to prevent or treat bacterial infectious diseases. Its product comprises of Pneumococcal conjugate vaccine. The firm's product candidate consists of VAX-31, VAX-24, VAX-A1, VAX-PG, VAX-GI, and Others.

Ticker

$PCVX
Primary listing

Industry

Biotechnology

Employees

414

ISIN

US92243G1085

Vaxcyte Metrics

BasicAdvanced
$4.8B
-
-$3.98
1.20
-

What the Analysts think about Vaxcyte

Analyst ratings (Buy, Hold, Sell) for Vaxcyte stock.

Bulls say / Bears say

Vaxcyte's VAX-31 vaccine candidate received FDA Breakthrough Therapy designation for adult indications, potentially expediting its development and approval process. (stocktitan.net)
The company successfully raised $1.5 billion through a public offering, significantly strengthening its financial position to support ongoing and future vaccine development programs. (finance.yahoo.com)
Vaxcyte's VAX-31 demonstrated a safety profile comparable to Pfizer's Prevnar 20 in a Phase 1/2 trial, indicating strong potential for competitive efficacy in the pneumococcal vaccine market. (seekingalpha.com)
Vaxcyte reported a net loss of $137.1 million for Q4 2024, reflecting the high costs associated with ongoing research and development activities. (stocktitan.net)
Insider selling activity, including the sale of 8,000 shares by COO Jim Wassil, may raise concerns about internal confidence in the company's short-term prospects. (techdows.com)
Despite positive developments, Vaxcyte's stock experienced a 3.24% decline following the announcement of its Q3 2024 financial results, suggesting potential investor apprehension regarding financial performance. (stocktitan.net)
Data summarised monthly by Lightyear AI. Last updated on 11 Jul 2025.

Vaxcyte Financial Performance

Revenues and expenses
QuarterlyAnnual
Q3 24
QoQ growth
Revenue
$37B
-39.75%
Net income
$45B
107.52%
Profit margin
37.65%
6.78%

Vaxcyte Earnings Performance

Company profitability
QuarterlyAnnual
Q4 23
Q1 24
Q2 24
Q3 24
Q4 24
Actual
$3.69
$2.85
$2.45
$2.42
-
Expected
$3.55
$2.61
$2.05
$2.31
$3.94
Surprise
3.94%
9.20%
19.51%
4.63%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PCVX

Sign up or log in to buy
Capital at risk
Market open

Upcoming events

No upcoming events
FAQs